Verquvo (vericiguat) / Bayer, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 2 Diseases   27 Trials   27 Trials   1089 News 


«12...345678910111213...1516»
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD), omecamtiv mecarbil (AMG 423) / Amgen, Servier
    Clinical, Review, Journal:  Where are we in 2021 with heart failure with reduced ejection fraction?-current outlook and expectations from new promising clinical trials. (Pubmed Central) -  Apr 30, 2022   
    Implementation of new substances for the HFrEF therapy makes it possible to formulate simple rules of treatment-in most cases, administering a dose of drug in one tablet provides a faster therapeutic effect. The aim of this article is to summarize current knowledge on recently announced findings on novel molecules and to propose a new revolutionary and individualised approach to treatment of HFrEF patients.
  • ||||||||||  Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
    Journal:  Pharmacological treatment options for heart failure with reduced ejection fraction: A 2022 update. (Pubmed Central) -  Apr 7, 2022   
    Finally, an important piece in the HF management puzzle is the treatment of its comorbidities. For instance, patients hospitalized for acute HF decompensation should be systematically screened for iron deficiency, since HF patients with proven iron deficiency benefit from intravenous ferric carboxymaltose.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD), omecamtiv mecarbil (AMG 423) / Amgen, Servier, Procoralan (ivabradine) / Amgen, Servier, Ono Pharma
    Retrospective data, Review, Journal:  A Systematic Review and Network-Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction. (Pubmed Central) -  Apr 5, 2022   
    For instance, patients hospitalized for acute HF decompensation should be systematically screened for iron deficiency, since HF patients with proven iron deficiency benefit from intravenous ferric carboxymaltose. In patients with HF with reduced ejection fraction, the estimated aggregate benefit is greatest for a combination of ARNi, BB, MRA, and SGLT2i.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD), Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
    Review, Journal:  Sacubitril/valsartan, sodium-glucose cotransporter 2 inhibitors, and vericiguat for congestive heart failure therapy. (Pubmed Central) -  Apr 5, 2022   
    None of the three drug classes was associated with a higher prevalence of treatment discontinuation due to increases in adverse effects in large-scale randomised clinical trials compared to placebo. Further studies are required to clarify the extent of effects of these medications in different subpopulations - especially in patients with mid-range and preserved ejection fraction.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    Journal, Real-world evidence:  Real-world eligibility for vericiguat in decompensated heart failure with reduced ejection fraction. (Pubmed Central) -  Mar 26, 2022   
    Conclusions Among the Korean hospitalized HFrEF patients, 94.9% met the FDA/EC label criteria, while 58% met the inclusion criteria of the VICTORIA trial. Our findings suggest the need for better strategies to integrate up-to-date HF treatment in a real-world HF population, especially decompensated HF patients with low SBP and non-elevated natriuretic peptide.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD), omecamtiv mecarbil (AMG 423) / Amgen, Servier
    Clinical, Review, Journal:  Evidence-Based Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease. (Pubmed Central) -  Mar 11, 2022   
    Last, although an initial decline in eGFR is observed on initiation of several HFrEF drug classes (angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers/mineralocorticoid receptor antagonists/angiotensin receptor blocker neprilysin inhibitors/sodium glucose cotransporter 2 inhibitors), renal function often stabilizes over time, and the drugs maintain their clinical efficacy. A decline in eGFR in the context of a stable or improving clinical condition should therefore not be cause for concern and should not lead to discontinuation of life-saving HFrEF therapies.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD), Procoralan (ivabradine) / Amgen, Servier, Ono Pharma
    Review, Journal:  Medical Management of Patients With Heart Failure and Reduced Ejection Fraction. (Pubmed Central) -  Mar 9, 2022   
    This review provides an overview of the medical management of patients with HFrEF with focus on the major developments that have taken place in the field. It offers prospective of how these drugs should be employed in clinical practice and also a glimpse into some strategies that may prove to be useful in the future.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    No vericiguat? (Twitter) -  Mar 7, 2022   
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    Journal:  Vericiguat erweitert das Therapiespektrum. (Pubmed Central) -  Feb 26, 2022   
    Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT02861534. No abstract available
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD), Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories, omecamtiv mecarbil (AMG 423) / Amgen, Servier
    Review, Journal:  Recent advances in pharmacological treatment of heart failure. (Pubmed Central) -  Feb 11, 2022   
    Active, not recruiting --> Completed This review aimed to revise the main novelties in the field of HF therapy and focus on how the daily clinical approach to patient treatment is changing.
  • ||||||||||  Vyndaqel (tafamidis meglumine) / Pfizer, Verquvo (vericiguat) / Bayer, Merck (MSD), Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
    Clinical, Journal:  Diagnosis and management of heart failure from hospital admission to discharge: A practical expert guidance. (Pubmed Central) -  Feb 4, 2022   
    Studies with tafamidis report major clinical benefits specifically for patients with ATTR cardiac amyloidosis, a remaining underdiagnosed and undertreated disease...In the community, new evidence supports that improving discharge education, treatment and patient support improves outcomes. The authors believe that this review fills the gap between the guidelines and clinical practice and provides practical recommendations to improve HF management.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    CLASSIFICATION AND IMPLICATIONS OF HEART FAILURE EVENTS FROM THE VICTORIA TRIAL (Heart Failure and Cardiomyopathies Moderated Poster Theater 12_Hall C) -  Jan 28, 2022 - Abstract #ACC2022ACC_3846;    
    HF events in large global trial vary significantly in severity and clinical implications. The treatment benefit of vericiguat was generally consistent across different HF event types.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD), omecamtiv mecarbil (AMG 423) / Amgen, Servier
    742 - Guidelines and Beyond: Therapies for Advancing HFrEF (Room 202B) -  Jan 28, 2022 - Abstract #ACC2022ACC_1170;    
    A panel discussion regarding the vignette will follow. Audience response will be re-employed at the end of the session.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD), Adempas (riociguat) / Bayer
    Discovery of MK-6158 an oral, once daily, Soluble Guanylate Cyclase (sGC) Stimulator for the treatment of Pulmonary Arterial Hypertension (Room 1A (San Diego Convention Center)) -  Jan 28, 2022 - Abstract #ACSSp2022ACS_Sp_4090;    
    Here we will present the discovery of MK-6158, a novel sGC stimulator that demonstrates high potency both in-vitro and in-vivo. We will discuss the SAR progression leading to the discovery of the clinical candidate with an optimized balanced clearance profile, a clean off-target profile needed to reduce the risk of drug-drug interaction, and a half-life in preclinical species compatible with once daily oral dosing.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD), omecamtiv mecarbil (AMG 423) / Amgen, Servier
    Retrospective data, Review, Journal:  Prognostic Benefit of New Drugs for HFrEF: A Systematic Review and Network Meta-Analysis. (Pubmed Central) -  Jan 26, 2022   
    In patients with HFrEF on standard-of-care therapy, SGLT2i therapy was associated with a reduced risk of CVD-HF compared to placebo, vericiguat, and omecamtiv mecarbil. Furthermore, SGLT2i were superior to placebo and omecamtiv mecarbil for CVD, all-cause death, and HFH, and also to vericiguat for HFH.
  • ||||||||||  Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
    Review, Journal:  A year in heart failure: an update of recent findings. (Pubmed Central) -  Jan 5, 2022   
    Landmark trials and the 2021 European Society of Cardiology guidelines for the diagnosis and treatment of HF have established four classes of drugs for treatment of HF with reduced ejection fraction: angiotensin-converting enzyme inhibitors or an angiotensin receptor-neprilysin inhibitor, beta-blockers, mineralocorticoid receptor antagonists, and sodium-glucose co-transporter 2 inhibitors, namely, dapagliflozin or empagliflozin...The guanylate cyclase activator vericiguat and the myosin activator omecamtiv mecarbil improved outcomes in randomized placebo-controlled trials, and vericiguat is now approved for clinical practice...Coronavirus disease 2019 (COVID-19) pandemic still plays a major role in HF epidemiology and management. All these aspects are highlighted in this review.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD), Procoralan (ivabradine) / Amgen, Servier, Ono Pharma
    Beyond the Basics of Heart Failure Management: Optimizing Guideline-Directed Medical Therapy (GDMT) to Make Heart Failure Functional ([VIRTUAL]) -  Dec 2, 2021 - Abstract #ASHP2021ASHP_4635;    
    Learning Objectives: Identify patients who are appropriate candidates for initiation of SGLT-2 inhibitors.Develop a plan to treat anemia in heart failure patient with iron supplementation therapy.Evaluate the risks and benefits of adding vericiguat to baseline heart failure treatment regimens.Recommnd a plan for the initiation and titration of ivabradine to meet heart failure treatment goals. Target Audience: Pharmacist Level of Content:Advanced Activity Type: Application-based